

GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030

PART I

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER ENDED 31ST MARCH, 2013

	Unaudited			(Rs. lakhs)
	3 months ended 31.03.2013	Preceding 3 months ended 31.12.2012	Corresponding 3 months ended 31.03.2012	Audited Year ended 31.12.2012
Income from Operations				
Net Sales (net of excise duty)	63214	65669	62278	259993
Other Operating Income (net of expenses relating to service income)	474	550	576	2650
Total Income from Operations (net)	63688	66219	62854	262643
Expenses				
Cost of materials consumed	11306	9271	10142	43781
Purchases of stock-in-trade	18663	17503	12351	60745
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(2631)	1258	3719	5259
Total materials consumed	27338	28032	26212	109785
Employee benefits expense	7908	7694	6500	29551
Depreciation	417	458	412	1784
Other expenses	12695	12119	10845	46319
Expenses relating to service income	(1015)	(1311)	(852)	(4539)
Total operating expenses	20005	18960	16905	73115
Total expenses	47343	46992	43117	182900
Profit from Operations before Other Income and Exceptional Items	16345	19227	19737	79743
Other Income	7696	4215	7465	19735
Profit from ordinary activities before Exceptional Items	24041	23442	27202	99478
Exceptional Items	(156)	(2969)	(9297)	(14822)
Profit from ordinary activities before tax	23885	20473	17905	84656
Tax Expense	6984	6622	5616	26930
Net Profit from ordinary activities	16901	13851	12289	57726
Paid-up Equity Share Capital (Face value per share Rs. 10)	8470	8470	8470	8470
Reserves excluding Revaluation Reserves				192531
Earnings Per Share (EPS) (of Rs. 10 each) (not annualised)				
Basic and diluted EPS (Rs.)	20.0	16.4	14.5	68.2

PART II

A. PARTICULARS OF SHAREHOLDING

Public Shareholding				
Number of shares	41785529	41785529	41785529	41785529
Percentage of shareholding	49.3%	49.3%	49.3%	49.3%
Promoters and promoter group Shareholding				
(a) Pledged/Encumbered				
- Number of shares	Nil	Nil	Nil	Nil
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil
- Percentage of shares (as a % of the total share capital of the company)	Nil	Nil	Nil	Nil
(b) Non-encumbered				
- Number of shares	42917488	42917488	42917488	42917488
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%
- Percentage of shares (as a % of the total share capital of the company)	50.7%	50.7%	50.7%	50.7%

Particulars	3 months ended 31.03.2013
B. INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	-
Received during the quarter	11
Disposed of during the quarter	11
Remaining unresolved at the end of the quarter	-

- The growth for the quarter was impacted by the core pharmaceuticals business which was flat compared to the same period last year. There was a significant impact on growth due to supply chain related issues.
- The Company has only one reportable segment which is Pharmaceuticals. Accordingly, no separate disclosures of segment information have been made.
- The above Results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors at their respective meetings held on 7th May, 2013.
- The figures for the quarter ended 31st December, 2012 are the balancing figures between the audited financial results for the year ended 31st December, 2012 and the published financial results for the nine months ended 30th September, 2012.
- The statutory auditors have carried out a limited review of the standalone results for the quarter ended 31st March, 2013.
- The figures for 2012 have been regrouped wherever necessary to facilitate comparison.

By Order of the Board

Dr. Hasit B. Joshipura
Managing Director

7th May, 2013